Article Versions Notes

Morioka I, Kakei Y, Omori T, Nozu K, Fujioka K, Takahashi N, Yoshikawa T, Moriuchi H, Ito Y, Oka A on behalf of the Japanese Congenital Cytomegalovirus Study Group. Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan. Journal of Clinical Medicine. 2022; 11(13):3582. https://doi.org/10.3390/jcm11133582

Morioka, Ichiro, Yasumasa Kakei, Takashi Omori, Kandai Nozu, Kazumichi Fujioka, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Yoshinori Ito, and Akira Oka on behalf of the Japanese Congenital Cytomegalovirus Study Group. 2022. "Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan" Journal of Clinical Medicine 11, no. 13: 3582. https://doi.org/10.3390/jcm11133582

Morioka, I., Kakei, Y., Omori, T., Nozu, K., Fujioka, K., Takahashi, N., Yoshikawa, T., Moriuchi, H., Ito, Y., & Oka, A., on behalf of the Japanese Congenital Cytomegalovirus Study Group. (2022). Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan. Journal of Clinical Medicine, 11(13), 3582. https://doi.org/10.3390/jcm11133582